Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells

N

Nanfang Hospital, Southern Medical University

Status

Unknown

Conditions

Chronic Myeloid Leukemia

Study type

Observational

Funder types

Other

Identifiers

NCT04991532
NFEC-2021-130

Details and patient eligibility

About

Research on the mechanism of dasatinib down-regulates the expression of PD-1 in CMV-activated NKG2C+NK cells and enhances killing pH + leukemia stem cells.

Full description

Some patients with CML can withdraw from TKIs after treatment, and the mechanism might be related to the effect of memory NK cells on anti-Ph+ leukemic stem cells (LSCs). Dasatinib affects immune through several pathways including the expression of PD1 in immune cells. Our previous work showed increased NKG2C+ NK cells were found in cases with CMV-DNA+ who suffered Ph+ leukemia and received Dasatinib, and these memory NK cells have anti-LSCs activity. We hypothesize that: CMV infection activates NKG2C+ memory NK cells proliferation; Dasatinib down-regulates the expression of PD1 in PD1+NKG2C+ NK cell subsets and then enhances anti-LSCs activity of these cells. In this study, the effect of Dasatinib on CMV-activated NKG2C+ cell subsets and its mechanism will be studies. Besides, the different NKG2C+ cell subsets on LSCs will be compared. This study might be helpful to clarify the mechanism of TKI withdrawal and to offer foundation for CMV and Ph+ ALL treatment strategies

Enrollment

324 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >18 years old, gender is not limited
  • CML-CP patients treated with TKIs
  • No pregnancy was planned during the treatment

Exclusion criteria

1.The researcher judged that it was not suitable to participate in this study

Trial design

324 participants in 2 patient groups

Dasatinib group
Description:
the CML patient treated with dasatinib
Imatinib group
Description:
the CML patient treated with imatinib

Trial contacts and locations

0

Loading...

Central trial contact

Weixiang Lu; Dan Xu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems